Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• Cartwright R, Brincker H, Carli P M, et al. The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 1999; 35: 627–633
   PubMed Web of Science ®Google Scholar
• Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014–1022
   PubMed Web of Science ®Google Scholar
• Peterson C G, Kahl B S. Follicular lymphoma: management options in the era of targeted therapy. Curr Treat Options Oncol 2005; 6: 297–308
   PubMedGoogle Scholar
• Montoto S, Moreno C, Domingo-Domenech E, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 2008; 93: 207–214
   PubMed Web of Science ®Google Scholar
• Hochster H S, Weller E, Gascoyne R D, et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG/CALGB intergroup E1496 trial. ASCO Annual Meeting Proc. Part I 2007; 25
   Google Scholar
• Gajraj E, Chung H, Longson C, et al. Rituximab for follicular non-Hodgkin lymphoma. Lancet Oncol 2008; 9: 320–321
   Google Scholar
• Sacchi S, Pozzi S, Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007; 110: 121–128
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661
   PubMed Web of Science ®Google Scholar
• Tam C S, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980
   PubMed Web of Science ®Google Scholar
• van de Wetering J K, van Golde L M, Batenburg J J. Collectins: players of the innate immune system. Eur J Biochem 2004; 271: 1229–1249
   PubMedGoogle Scholar
• Dommett R M, Klein N, Turner M W. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006; 68: 193–209
   PubMed Web of Science ®Google Scholar
• Neth O, Jack D L, Dodds A W, et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68: 688–693
   PubMed Web of Science ®Google Scholar
• Thiel S, Steffensen R, Christensen I J, et al. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun 2007; 8: 154–163
   PubMed Web of Science ®Google Scholar
• Garred P, Larsen F, Madsen H O, et al. Mannose-binding lectin deficiency–revisited. Mol Immunol 2003; 40: 73–84
   PubMed Web of Science ®Google Scholar
• Verdu P, Barreiro L B, Patin E, et al. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet 2006; 15: 2650–2658
   PubMed Web of Science ®Google Scholar
• Steffensen R, Thiel S, Varming K, et al. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000; 241: 33–42
   PubMed Web of Science ®Google Scholar
• Boldt A B, Culpi L, Tsuneto L T, et al. Diversity of the MBL2 gene in various Brazilian populations and the case of selection at the mannose-binding lectin locus. Hum Immunol 2006; 67: 722–734
   PubMed Web of Science ®Google Scholar
• Minchinton R M, Dean M M, Clark T R, et al. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002; 56: 630–641
   PubMed Web of Science ®Google Scholar
• Naito H, Ikeda A, Hasegawa K, et al. Characterization of human serum mannan-binding protein promoter. J Biochem 1999; 126: 1004–1012
   PubMed Web of Science ®Google Scholar
• Garred P. Mannose-binding lectin genetics: from A to Z. Biochem Soc Trans 2008; 36: 1461–1466
   PubMed Web of Science ®Google Scholar
• Garred P, Thiel S, Madsen H O, et al. Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. Clin Exp Immunol 1992; 90: 517–521
   PubMed Web of Science ®Google Scholar
• Granell M, Urbano-Ispizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 2006; 34: 1435–1441
   PubMed Web of Science ®Google Scholar
• Schlapbach L J, Aebi C, Otth M, et al. Deficiency of mannose-binding lectin-associated serine protease-2 associated with increased risk of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2007; 26: 989–994
   PubMed Web of Science ®Google Scholar
• Molle I, Steffensen R, Thiel S, et al. Chemotherapy-related infections in patients with multiple myeloma: associations with mannan-binding lectin genotypes. Eur J Haematol 2006; 77: 19–26
   PubMed Web of Science ®Google Scholar
• Bouwman L H, Roos A, Terpstra O T, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408–414
   PubMed Web of Science ®Google Scholar
• Chong W P, To Y F, Ip W K, et al. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005; 42: 1037–1045
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen H O. Genetic susceptibility to sepsis: a possible role for mannose-binding lectin. Curr Infect Dis Rep 2004; 6: 367–373
   PubMedGoogle Scholar
• Jaffe E S, Harris N L, Stein H, et al. WHO Classification of Tumours. IARC Press, Lyon 2001; 3
   Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Steffensen R, Hoffmann K, Varming K. Rapid genotyping of MBL2 gene mutations using real-time PCR with fluorescent hybridisation probes. J Immunol Methods 2003; 278: 191–199
   PubMed Web of Science ®Google Scholar
• Fisher R I, LeBlanc M, Press O W, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Pulsoni A, Gentilini P, et al. Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2004; 45: 1815–1819
   PubMed Web of Science ®Google Scholar
• Flinn I W, Neuberg D S, Grever M R, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793–798
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Garred P, Madsen H O, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236–240
   PubMed Web of Science ®Google Scholar
• Garred P, Richter C, Andersen A B, et al. Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scand J Immunol 1997; 46: 204–208
   PubMed Web of Science ®Google Scholar
• Saifuddin M, Hart M L, Gewurz H, et al. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000; 81: 949–955
   PubMed Web of Science ®Google Scholar
• Molle I, Peterslund N A, Thiel S, et al. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 555–560
   PubMed Web of Science ®Google Scholar
• Madsen H O, Satz M L, Hogh B, et al. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998; 161: 3169–3175
   PubMed Web of Science ®Google Scholar
• Ross S R, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 1993; 45: 737–759
   PubMed Web of Science ®Google Scholar
• Hummelshoj T, Munthe-Fog L, Madsen H O, et al. Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet 2005; 14: 1651–1658
   PubMed Web of Science ®Google Scholar
• Figueroa J E, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4: 359–395
   PubMed Web of Science ®Google Scholar
• Sorensen C M, Hansen T K, Steffensen R, et al. Hormonal regulation of mannan-binding lectin synthesis in hepatocytes. Clin Exp Immunol 2006; 145: 173–182
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Gondo H, Miyagawa H, et al. Association of MBL gene polymorphisms with mayor bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 2005; 6: 162–166
   PubMed Web of Science ®Google Scholar